Kirin Holdings Company (2503) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Q1 FY2026 revenue rose 5.0% year-over-year to ¥573.0 billion, with normalized operating profit up 37.7% to ¥50.0 billion and profit attributable to owners up 11.3% to ¥27.1 billion.
EPS increased 11.3% to ¥33, progressing steadily against the annual plan.
Comprehensive income surged to ¥76.4 billion from a loss of ¥18.9 billion in Q1 2025, driven by strong foreign currency translation gains.
Growth was driven by strong performance in pharmaceuticals, health science, and overseas alcoholic beverages, offsetting domestic declines.
Financial highlights
Revenue: ¥573.0 billion (+5.0% YoY); Normalized OP: ¥50.0 billion (+37.7% YoY); Profit before tax: ¥50.3 billion (+31.6% YoY).
Gross profit increased 9.2% YoY to ¥276.9 billion; operating profit rose 28.0% to ¥39.7 billion.
EPS improved to ¥33.46 from ¥30.05, an 11.3% increase.
Operating cash flow improved to ¥74.2 billion, up ¥64.0 billion YoY; free cash flow turned positive at ¥48.6 billion.
Equity ratio attributable to owners improved to 38.7% from 36.8% at year-end 2025.
Outlook and guidance
No revisions to the full-year forecast; EPS target of ¥193 maintained.
FY2026 revenue is forecast at ¥2,480.0 billion (+1.9% YoY), normalized operating profit at ¥235.0 billion (-6.7%), and profit attributable to owners at ¥156.0 billion (+5.7%).
Dividend forecast raised to ¥76.00 per share for FY2026.
Structural reforms and business optimization ongoing; positive factors include R&D cost reductions and gains from business sales.
Risks include rising raw material/fuel costs and losses from business divestitures.
Latest events from Kirin Holdings Company
- Profit more than doubled, Health Science turned profitable, and major portfolio moves were made.2503
Q4 202513 Feb 2026 - Targets high single-digit EPS growth, ROIC ≥10%, and 3 trillion yen market cap by 2035.2503
Investor presentation13 Feb 2026 - Double-digit revenue and profit growth, but profit guidance trimmed on higher taxes.2503
Q2 202425 Jan 2026 - Profit and revenue up, FANCL fully consolidated, Health Science segment surges.2503
Q3 202511 Nov 2025 - Revenue rose 3.7% YoY, but profit and EPS fell on restructuring and FX impacts.2503
Q2 20257 Aug 2025 - Revenue and operating profit rose, but net profit dropped on FANCL acquisition loss.2503
Q3 202413 Jun 2025 - Revenue and profit grew, but net income fell on FX and equity changes from FANCL buyout.2503
Q1 20256 Jun 2025 - FY2025 profit is set to rebound sharply, driven by Health Science and Alcoholic Beverages.2503
Q4 20245 Jun 2025